Published in Antimicrob Agents Chemother on February 01, 2001
What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev (2002) 5.81
Ribosomal mutations in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother (2002) 1.63
Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol (2006) 1.48
recA-based PCR assay for accurate differentiation of Streptococcus pneumoniae from other viridans streptococci. J Clin Microbiol (2010) 1.07
In vitro activity of telithromycin against viridans group streptococci and Streptococcus bovis isolated from blood: antimicrobial susceptibility patterns in different groups of species. Antimicrob Agents Chemother (2005) 0.86
New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae. Antimicrob Agents Chemother (2010) 0.75
Classification and identification of the viridans streptococci. Clin Microbiol Rev (1989) 2.70
Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis (1994) 2.61
Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother (1996) 2.22
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother (1998) 1.80
In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother (1998) 1.67
In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother (1998) 1.63
Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis (1992) 1.61
Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med (1994) 1.53
Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis (1992) 1.50
Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection (1990) 1.39
In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria. Antimicrob Agents Chemother (1999) 1.38
Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis (1995) 1.36
In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother (1995) 1.35
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Agents Chemother (1996) 1.20
Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother (1999) 1.07
Nomenclature for aerobic and facultative bacteria. Clin Infect Dis (1997) 1.04
Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis (1996) 1.04
Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med (1990) 1.03
Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection (1990) 1.00
A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother (1994) 0.91
Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol (1993) 0.89
Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1998) 0.89
Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis. Antimicrob Agents Chemother (1999) 0.79
Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci U S A (1989) 5.65
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med (1995) 4.38
Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis (1992) 3.37
Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol (2000) 3.23
Pathogenesis of catheter sepsis: a prospective study with quantitative and semiquantitative cultures of catheter hub and segments. J Clin Microbiol (1985) 3.14
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother (1992) 2.86
Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med (1987) 2.78
Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems. Antimicrob Agents Chemother (1998) 2.60
Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1998) 2.40
Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet (1999) 2.30
Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol (1997) 2.24
Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med (1988) 2.24
Evaluation of the BACTEC MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA AccuProbe. J Clin Microbiol (2000) 2.23
Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother (1991) 2.13
Specific antibody profile in human brucellosis. Clin Infect Dis (1992) 2.08
[Current treatment of pneumococcal meningitis]. Enferm Infecc Microbiol Clin (1991) 2.02
Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother (1998) 2.00
Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. Eur Respir J (2002) 2.00
Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med (1999) 1.96
Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis (2003) 1.92
Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1994) 1.85
Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol (2013) 1.79
Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis (1996) 1.68
Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis (1995) 1.67
Streptococcal meningitis in adult patients: current epidemiology and clinical spectrum. Clin Infect Dis (1999) 1.66
Antibiotic resistance and serotypes of Streptococcus pneumoniae from patients with community-acquired pneumococcal disease. Antimicrob Agents Chemother (1983) 1.65
Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother (1985) 1.63
Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med (1996) 1.61
Risk factors for nosocomial Legionella pneumophila pneumonia. Am J Respir Crit Care Med (1994) 1.61
Human milk: a source of more life than we imagine. Benef Microbes (2013) 1.58
Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect (1997) 1.58
Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med (1992) 1.58
Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med (1995) 1.58
Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother (1998) 1.58
Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.52
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother (1996) 1.51
Presence of nitric oxide synthase activity in roots and nodules of Lupinus albus. FEBS Lett (1996) 1.49
Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. Clin Infect Dis (1992) 1.47
[Cytomegalovirus disease in patients with acquired immunodeficiency syndrome. Report of 63 cases]. Med Clin (Barc) (1993) 1.47
[Telematics and neurology]. Rev Neurol (1996) 1.40
[Inflammatory pseudotumor of the liver presenting as fever of unknown origin]. Med Clin (Barc) (2001) 1.39
[The polymerase chain reaction as a marker of cytomegalovirus infection in heart transplant recipients]. Med Clin (Barc) (1999) 1.38
[Cerebral blood flow study using SPECT in patients with memory disorders]. Rev Neurol (1997) 1.38
Antimicrobial potential of four Lactobacillus strains isolated from breast milk. J Appl Microbiol (2006) 1.38
[Rapid and slow progression of the infection by the type 1 human immunodeficiency virus in a population of seropositive subjects in Madrid]. Med Clin (Barc) (1996) 1.38
Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine. AIDS (2000) 1.38
Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother (2010) 1.38
Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis (1995) 1.36
In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother (1995) 1.35
The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy (2009) 1.34
Specific antibodies detected during relapse of human brucellosis. J Infect Dis (1988) 1.33
A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. J Infect Dis (1997) 1.33
Hub colonization as the initial step in an outbreak of catheter-related sepsis due to coagulase negative staphylococci during parenteral nutrition. JPEN J Parenter Enteral Nutr (1985) 1.32
In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother (1986) 1.32
Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis (2001) 1.30
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. Antimicrob Agents Chemother (2007) 1.28
Gram-negative bacillary cellulitis in patients with hepatic cirrhosis. Eur J Clin Microbiol Infect Dis (1994) 1.27
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis (1995) 1.27
Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother (2002) 1.26
Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: similarities and differences on presentation. Eur Respir J (1989) 1.26
Antibiotic resistance of Streptococcus pneumoniae in childhood carriers. J Antimicrob Chemother (1987) 1.26
Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J Comp Neurol (1998) 1.26
Dopamine D5 receptors of rat and human brain. Neuroscience (2000) 1.25
Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season. Clin Microbiol Infect (2012) 1.24
Comparison of two leukocyte extraction methods for cytomegalovirus antigenemia assay. J Clin Microbiol (1996) 1.24
Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect (2008) 1.23
Effect of delayed processing of blood samples on performance of cytomegalovirus antigenemia assay. J Clin Microbiol (1994) 1.22
Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis (2000) 1.21
In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Agents Chemother (1996) 1.20
Pneumococcal peritonitis in adult patients: report of 64 cases with special reference to emergence of antibiotic resistance. Arch Intern Med (2001) 1.19
Group B streptococcal disease in nonpregnant adults: incidence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis (2004) 1.18
Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis (2000) 1.18
Usefulness of PCR and antigen latex agglutination test with samples obtained by transthoracic needle aspiration for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1999) 1.17
Two Lactobacillus strains, isolated from breast milk, differently modulate the immune response. J Appl Microbiol (2007) 1.17
Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect (2012) 1.16
Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect (2006) 1.16
Nosocomial spread of Pseudomonas aeruginosa producing the metallo-beta-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clin Microbiol Infect (2007) 1.16
Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother (1986) 1.16